Skip to content

Released Mar 5, 2026, before the open

10-K filed Mar 5, 2026, 64 days after period end · 0001171843-26-001337

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$15.72MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$17,990,000N/M
Operating Cash Flowderived-$13,254,000N/M
Free Cash Flowderived-$13,254,000N/M

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figures
Net Income-$15.72M-$15.03M-$13.42M-$11.59M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR